Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: Meta-regression analysis of 78 randomized controlled trials with 20, 053 patients

Endocrine

Volumn 46, Issue 1, 2014, Pages 43-51

  Esposito, Katherine ^a   Chiodini, Paolo ^a   Capuano, Annalisa ^a   Maiorino, Maria Ida ^a   Bellastella, Giuseppe ^a   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

DPP 4 inhibitors; HbA1c response; Randomized controlled trial; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

AGE; ARTICLE; DRUG RESPONSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PLACEBO EFFECT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AGING; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84898771392     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0090-0     Document Type: Article

References (24)

1. D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94, 311-321 (2011)
2. A.S. Go, D. Mozaffarian, V.L. Roger et al., On behalf of the American Heart Association Statistics Committee an Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013)
3. K. Esposito, A. Ceriello, D. Giugliano, Does personalized dia-betology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? Endocrine (2013). doi:10.1007/s12020-013-9918-x
4. T. Karagiannis, P. Paschos, K. Paletas, D.R. Matthews, A. Tsapas, Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344, e1369 (2013)
5. Y. Takeda, Y. Fujita, J. Honjo, T. Yanagimachi, H. Sakagami, Y. Takiyama, Y. Makino, A. Abiko, T.J. Kieffer, M. Haneda, Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55, 404-412 (2012)
6. M.A. Nauck, Incretin-based therapies for type 2 diabetes melli-tus: properties, functions, and clinical implications. Am. J. Med. 124, S3-S18 (2011)
7. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Fer-rannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, Matthews, Management of hyperglycemia in type 2 diabetes: a patient centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care 35, 1364-1379 (2012)
8. American Association of Clinical Endocrinologists, AACE comprehensive diabetes management algorithm. Endocr. Pract. 19, 331 (2013)
9. O.J. Phung, J.M. Scholle, M. Talwar, G.I. Coleman, Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303, 1410-1418 (2010)
10. J.L. Gros, C.K. Kramer, C.B. Leitaõ, N. Hawkins, L.V. Viana, B.D. Schaan, L.C. Pinto, T.C. Rodrigues, M.J. Azevedo, For the Diabetes and Endocrinology Meta-analysis Group (DEMA): effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann. Intern. Med. 154, 672-679 (2011)
11. K. Esposito, P. Chiodini, G. Bellastella, M.I. Maiorino, D. Giugliano, Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78, 945 patients. Diabetes Obes. Metab. 14, 228-233 (2012)
12. J.J. Goldberger, A.E. Buxton, Personalized medicine vs guideline-based medicine. JAMA 309, 2559-2560 (2013)
13. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151, W65-W94 (2009)
14. A.D. Deeks, M.J. Bradburn, Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis, in Systematic Reviews in Health Care, ed. by M.D.-S.G. Egger, D.G. Altman (BMJ Publishing, London, 2001), pp. 285-312
15. H.C. Van Houwelingen, L.R. Arends, T. Stijne, Advanced methods in meta-analysis: multivariate approach and metaregression. Stat. Med. 21, 589-624 (2002)
16. J.P. Higgins, S.G. Thompson, Controlling the risk of spurious findings from metaregression. Stat. Med. 23, 1663-1682 (2004)
17. M.K. Ali, K. McKeever Bullard, J.B. Saaddine, C.C. Cowie, G. Imperatore, E.W. Gregg, Achievement of goals in U.S. diabetes care, 1999-2010. N. Engl. J. Med. 368, 1613-1624 (2013)
18. I. Raz, M.C. Riddle, J. Rosenstock, J.B. Buse, S.E. Inzucchi, P.D. Home, S. Del Prato, E. Ferrannini, J.C. Chan, L.A. Leiter, D. Leroith, R. Defronzo, W.T. Cefalu, Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors' expert forum. Diabetes Care 36, 1779-1788 (2013)
19. A.J. Scheen, G. Charpentier, C.J. Ostgren, A. Hellqvist, I. Gause-Nilsson, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with met-formin in adult patients with type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 26, 540-549 (2010)
20. B. Göke, K. Hershon, D. Kerr, A. Calle Pascual, A. Schweizer, J. Foley, Q. Shao, S. Dejager, Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm. Metab. Res. 40, 892-895 (2008)
21. D. Williams-Herman, J. Johnson, R. Teng, G. Golm, K.D. Kaufman, B.J. Goldstein, J.M. Amatruda, Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes. Metab. 12, 442-451 (2010)
22. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mozenson, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, The SAVOR-TIMI 53 Steering Committee and Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317-1326 (2013)
23. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Ber-genstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, The EXAMINE Investigators, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327-1335 (2013)
24. C. Ess, F. Sudweeks, Culture, Technology, Communication: Towards an Intercultural Global Village (SUNY Press, Albany, 2001), p. 90